The company's lead drug candidate, NRP2945, is currently in a Phase II study for adults with typical absence epilepsy, and the company is seeking investment to conduct a Phase II study in Temporal Lobe Epilepsy and Lennox-Gastaut Syndrome children. NRP2945 works on a unique MOA, exerting its activity via agonism of a novel CXCR4 receptor complex in an ultra-potent manner with no off-target effects. It is neuroregenerative and neuroprotective, enhancing memory consolidation and retrieval, and downregulating anxiety and hyperactivity profiles. The drug has good prospects to be developed for orphan motor diseases like ALS or other childhood encephalopathies.